A citation-based method for searching scientific literature


List of co-cited articles
3 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Jeffrey S Weber, Sandra P D'Angelo, David Minor, F Stephen Hodi, Ralf Gutzmer, Bart Neyns, Christoph Hoeller, Nikhil I Khushalani, Wilson H Miller, Christopher D Lao,[...]. Lancet Oncol 2015
66

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
Jeffrey Weber, Mario Mandala, Michele Del Vecchio, Helen J Gogas, Ana M Arance, C Lance Cowey, Stéphane Dalle, Michael Schenker, Vanna Chiarion-Sileni, Ivan Marquez-Rodas,[...]. N Engl J Med 2017
66

Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Caroline Robert, Jacob Schachter, Georgina V Long, Ana Arance, Jean Jacques Grob, Laurent Mortier, Adil Daud, Matteo S Carlino, Catriona McNeil, Michal Lotem,[...]. N Engl J Med 2015
66

Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.
Axel Hauschild, Paolo A Ascierto, Dirk Schadendorf, Jean Jacques Grob, Antoni Ribas, Felix Kiecker, Caroline Dutriaux, Lev V Demidov, Céleste Lebbé, Piotr Rutkowski,[...]. Eur J Cancer 2020
25
33


Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.
Alexander M M Eggermont, Christian U Blank, Mario Mandalà, Georgina V Long, Victoria G Atkinson, Stéphane Dalle, Andrew M Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S Carlino,[...]. Lancet Oncol 2021
57
33

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.
Georgina V Long, Reinhard Dummer, Omid Hamid, Thomas F Gajewski, Christian Caglevic, Stephane Dalle, Ana Arance, Matteo S Carlino, Jean-Jacques Grob, Tae Min Kim,[...]. Lancet Oncol 2019
375
33


Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial.
Alexander M M Eggermont, Christian U Blank, Mario Mandala, Georgina V Long, Victoria G Atkinson, Stéphane Dalle, Andrew M Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S Carlino,[...]. J Clin Oncol 2020
93
33

Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.
Neil N Senzer, Howard L Kaufman, Thomas Amatruda, Mike Nemunaitis, Tony Reid, Gregory Daniels, Rene Gonzalez, John Glaspy, Eric Whitman, Kevin Harrington,[...]. J Clin Oncol 2009
429
33

Adjusting for the Confounding Effects of Treatment Switching-The BREAK-3 Trial: Dabrafenib Versus Dacarbazine.
Nicholas R Latimer, Keith R Abrams, Mayur M Amonkar, Ceilidh Stapelkamp, R Suzanne Swann. Oncologist 2015
18
33

KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma.
Jason J Luke, Paolo A Ascierto, Matteo S Carlino, Jeffrey E Gershenwald, Jean-Jacques Grob, Axel Hauschild, John M Kirkwood, Georgina V Long, Peter Mohr, Caroline Robert,[...]. Future Oncol 2020
25
33

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.
O Hamid, C Robert, A Daud, F S Hodi, W J Hwu, R Kefford, J D Wolchok, P Hersey, R Joseph, J S Weber,[...]. Ann Oncol 2019
275
33

Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma.
Caroline Robert, Keith Flaherty, Paul Nathan, Peter Hersey, Claus Garbe, Mohammed Milhem, Lev Demidov, Peter Mohr, Jessica C Hassel, Piotr Rutkowski,[...]. Eur J Cancer 2019
20
33

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Frank Stephen Hodi, Vanna Chiarion-Sileni, Rene Gonzalez, Jean-Jacques Grob, Piotr Rutkowski, Charles Lance Cowey, Christopher D Lao, Dirk Schadendorf, John Wagstaff, Reinhard Dummer,[...]. Lancet Oncol 2018
682
33

OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer.
Juan Deng, Sha Zhao, Xiaoshen Zhang, Keyi Jia, Hao Wang, Caicun Zhou, Yayi He. Onco Targets Ther 2019
22
33

Efficacy of Neoadjuvant Intratumoral Darleukin/Fibromun (L19IL2 + L19TNF) in Patients with Clinical Stage IIIB/C Melanoma (Neo-DREAM).
Areeba Saif, Alexander J Rossi, Amod Sarnaik, Jonathan M Hernandez, Jonathan S Zager. Ann Surg Oncol 2022
1
100

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
Georgina V Long, Victoria Atkinson, Jonathan S Cebon, Michael B Jameson, Bernie M Fitzharris, Catriona M McNeil, Andrew G Hill, Antoni Ribas, Michael B Atkins, John A Thompson,[...]. Lancet Oncol 2017
153
33

Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade.
Allison Betof Warner, Jessica S Palmer, Alexander N Shoushtari, Debra A Goldman, Katherine S Panageas, Sara A Hayes, Raazi Bajwa, Parisa Momtaz, Margaret K Callahan, Jedd D Wolchok,[...]. J Clin Oncol 2020
80
33

A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers.
Adi Diab, Omid Hamid, John A Thompson, Willeke Ros, Ferry A L M Eskens, Toshihiko Doi, Siwen Hu-Lieskovan, Samuel J Klempner, Bishu Ganguly, Catherine Fleener,[...]. Clin Cancer Res 2022
6
33

Current state of melanoma diagnosis and treatment.
Lauren E Davis, Sara C Shalin, Alan J Tackett. Cancer Biol Ther 2019
129
33

Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma.
Douglas B Johnson, Igor Puzanov, Mark C Kelley. Immunotherapy 2015
89
33

Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design.
Nikhil I Khushalani, Adi Diab, Paolo A Ascierto, James Larkin, Shahneen Sandhu, Mario Sznol, Henry B Koon, Anthony Jarkowski, Ming Zhou, Paul Statkevich,[...]. Future Oncol 2020
11
33

Current and emerging treatment options for metastatic melanoma: a focused review.
Khoa Nguyen, Emma Hignett, Amor Khachemoune. Dermatol Online J 2020
5
33

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.
Andrew Bottomley, Corneel Coens, Justyna Mierzynska, Christian U Blank, Mario Mandalà, Georgina V Long, Victoria G Atkinson, Stéphane Dalle, Andrew M Haydon, Andrey Meshcheryakov,[...]. Lancet Oncol 2021
7
33

Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma.
Stephanie L Goff, Mark E Dudley, Deborah E Citrin, Robert P Somerville, John R Wunderlich, David N Danforth, Daniel A Zlott, James C Yang, Richard M Sherry, Udai S Kammula,[...]. J Clin Oncol 2016
201
33

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.
Caroline Robert, Antoni Ribas, Jacob Schachter, Ana Arance, Jean-Jacques Grob, Laurent Mortier, Adil Daud, Matteo S Carlino, Catriona M McNeil, Michal Lotem,[...]. Lancet Oncol 2019
434
33

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.
Alexander M M Eggermont, Christian U Blank, Mario Mandala, Georgina V Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Mikhail Lichinitser, Adnan Khattak, Matteo S Carlino,[...]. N Engl J Med 2018
884
33

Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.
Paolo A Ascierto, Michele Del Vecchio, Mario Mandalá, Helen Gogas, Ana M Arance, Stephane Dalle, C Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion-Sileni,[...]. Lancet Oncol 2020
147
33

An Overview of the Changing Landscape of Treatment for Advanced Melanoma.
Chung-Shien Lee, Christan M Thomas, Kimberly E Ng. Pharmacotherapy 2017
21
33

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
Antoni Ribas, Igor Puzanov, Reinhard Dummer, Dirk Schadendorf, Omid Hamid, Caroline Robert, F Stephen Hodi, Jacob Schachter, Anna C Pavlick, Karl D Lewis,[...]. Lancet Oncol 2015
33

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma.
Adi Diab, Scott S Tykodi, Gregory A Daniels, Michele Maio, Brendan D Curti, Karl D Lewis, Sekwon Jang, Ewa Kalinka, Igor Puzanov, Alexander I Spira,[...]. J Clin Oncol 2021
21
33

T cell-induced CSF1 promotes melanoma resistance to PD1 blockade.
Natalie J Neubert, Martina Schmittnaegel, Natacha Bordry, Sina Nassiri, Noémie Wald, Christophe Martignier, Laure Tillé, Krisztian Homicsko, William Damsky, Hélène Maby-El Hajjami,[...]. Sci Transl Med 2018
156
33

Recent Advances in the Treatment of Melanoma.
Brendan D Curti, Mark B Faries. N Engl J Med 2021
48
33

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.
Kyung Hae Jung, Patricia LoRusso, Howard Burris, Michael Gordon, Yung-Jue Bang, Matthew D Hellmann, Andrés Cervantes, Maria Ochoa de Olza, Aurelien Marabelle, F Stephen Hodi,[...]. Clin Cancer Res 2019
103
33

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
Julie Westerlin Kjeldsen, Cathrine Lund Lorentzen, Evelina Martinenaite, Eva Ellebaek, Marco Donia, Rikke Boedker Holmstroem, Tobias Wirenfeldt Klausen, Cecilie Oelvang Madsen, Shamaila Munir Ahmed, Stine Emilie Weis-Banke,[...]. Nat Med 2021
13
33

Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors.
Bonnie S Glisson, Rom S Leidner, Robert L Ferris, John Powderly, Naiyer A Rizvi, Bhumsuk Keam, Reva Schneider, Sanjay Goel, James P Ohr, Jennifer Burton,[...]. Clin Cancer Res 2020
29
33

Targeting the PSGL-1 Immune Checkpoint Promotes Immunity to PD-1-Resistant Melanoma.
Julia M DeRogatis, Karla M Viramontes, Emily N Neubert, Monique L Henriquez, Christian F Guerrero-Juarez, Roberto Tinoco. Cancer Immunol Res 2022
3
33

Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.
Pippa G Corrie, Andrea Marshall, Janet A Dunn, Mark R Middleton, Paul D Nathan, Martin Gore, Neville Davidson, Steve Nicholson, Charles G Kelly, Maria Marples,[...]. Lancet Oncol 2014
74
33

Phase II study of nab-paclitaxel and bevacizumab as first-line therapy for patients with unresectable stage III and IV melanoma.
Lynn E Spitler, Peter Boasberg, Steven O'Day, Omid Hamid, Scott Cruickshank, Shane Mesko, Robert W Weber. Am J Clin Oncol 2015
28
33

A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients.
Benjamin Weide, Thomas Eigentler, Chiara Catania, Paolo Antonio Ascierto, Stefano Cascinu, Jürgen C Becker, Axel Hauschild, Antonella Romanini, Riccardo Danielli, Reinhard Dummer,[...]. Cancer Immunol Immunother 2019
22
33

Incidence, mortality and survival in cutaneous melanoma.
A-V Giblin, J M Thomas. J Plast Reconstr Aesthet Surg 2007
130
33


Pembrolizumab for Unresectable or Metastatic Melanoma in Patients Older than 85 Years of Age.
Johan Chanal, Nora Kramkimel, Carole Ratour, Selim Aractingi, Sarah Guégan, Marie-Françoise Avril. Dermatology 2019
6
33

Cutaneous Melanoma-A Review in Detection, Staging, and Management.
Rebecca I Hartman, Jennifer Y Lin. Hematol Oncol Clin North Am 2019
33
33

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
Jacob Schachter, Antoni Ribas, Georgina V Long, Ana Arance, Jean-Jacques Grob, Laurent Mortier, Adil Daud, Matteo S Carlino, Catriona McNeil, Michal Lotem,[...]. Lancet 2017
681
33

Rational design of anti-GITR-based combination immunotherapy.
Roberta Zappasodi, Cynthia Sirard, Yanyun Li, Sadna Budhu, Mohsen Abu-Akeel, Cailian Liu, Xia Yang, Hong Zhong, Walter Newman, Jingjing Qi,[...]. Nat Med 2019
103
33

Hedgehog inhibitors in the treatment of advanced basal cell carcinoma: risks and benefits.
Alessia Villani, Eleonora Cinelli, Gabriella Fabbrocini, Aimilios Lallas, Massimiliano Scalvenzi. Expert Opin Drug Saf 2020
16
33

Treatment of Advanced Melanoma in 2020 and Beyond.
Russell W Jenkins, David E Fisher. J Invest Dermatol 2021
74
33

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
Georgina V Long, Axel Hauschild, Mario Santinami, Victoria Atkinson, Mario Mandalà, Vanna Chiarion-Sileni, James Larkin, Marta Nyakas, Caroline Dutriaux, Andrew Haydon,[...]. N Engl J Med 2017
745
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.